Mitazalimab
Based on 1 publication(s) in Google Scholar
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.23%
- CAS 番号: 2055640-86-1
- 分子量:143.44 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Mitazalimab
More
生物活性
Human IgG1 lambda2
Human
|
CD40 |
Mitazalimab (1 ng/mL-10 μg/mL) activates tumor associated macrophages (TAMs) in prostate tumor or ovarian tumor samples from human[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mitazalimab (100 and 300 μg/mouse, i.p.; on day 7, 10 and 13 post-inoculation) induces the release of proinfammatory cytokines and chemokines in the blood in MB49 (mouse bladder tumor cell line) bearing mice, and alters the composition of tumor myeloid cells, such that reduces monocytes and macrophages in favor of granulocytic cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MB49-tumor bearing mice model[1]
-
Dosage:10, 30, 100 or 300 µg/mouse
-
Administration:Intraperitoneal injection; on day 7, 10 and 13 post-inoculation; sampled at 24 h after final dose
-
Result:Increased the level of IP-10, MIP-1α and TNF-α, but not CXCL1, IFN-γ, IL-6, IL-10, MCP-1 and MIP-2.
Resulted in increased frequency of CD44hi CD62L-efector memory CD8+ and CD4+ T cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling TNFRSF5/CD40 (red) with Mitazalimab (anti-TNFRSF5/CD40) (HY-P99742). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda2 (HY-P990096). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 2055640-86-1
-
性状 Liquid
-
分子量 143.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Mitazalimab]
-
別名
ADC-1013; JNJ-64457107; Vanalimab
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Control Release
Fibrin gel-based co-delivery of self-adjuvant tumor vaccine and PD-1 blockade for post-surgical gastric cancer immunotherapy. [Abstract]2026 Mar 10:391:114629. PMID: 41544668
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Deronic A, et al. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Mitazalimab 関連分類
HY-P99742 関連分類
Powered by Bioz